Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03331731
Title A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (PLIMATH)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Peter MacCallum Cancer Centre, Australia
Indications

Hodgkin's lymphoma

Therapies

Pembrolizumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.